618 related articles for article (PubMed ID: 17140358)
1. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
Doern GV
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
[TBL] [Abstract][Full Text] [Related]
2. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
3. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
Lode H
Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial drug use and resistance among respiratory pathogens in the community.
Low DE
Clin Infect Dis; 2001 Sep; 33 Suppl 3():S206-13. PubMed ID: 11524720
[TBL] [Abstract][Full Text] [Related]
5. Short-duration therapy for respiratory tract infections.
Goff DA
Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic resistance in community-acquired respiratory tract infections: current issues.
Spach DH; Black D
Ann Allergy Asthma Immunol; 1998 Oct; 81(4):293-302; quiz 302-3. PubMed ID: 9809491
[TBL] [Abstract][Full Text] [Related]
7. Primary care challenges in the management of respiratory tract infections.
JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of antibiotic resistance in respiratory tract infections.
Klugman KP
Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
[TBL] [Abstract][Full Text] [Related]
9. Managing acute lower respiratory tract infections in an era of antibacterial resistance.
Volturo GA; Low DE; Aghababian R
Am J Emerg Med; 2006 May; 24(3):329-42. PubMed ID: 16635707
[TBL] [Abstract][Full Text] [Related]
10. Meeting the challenge of antibiotic resistance: The PROTEKT US study.
Stratton CW
Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
14. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
Calbo E; Garau J
Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
[TBL] [Abstract][Full Text] [Related]
15. Treatment recommendations for patients with common respiratory tract infections with variables indicative of treatment failure.
Basri RS; Weiland DA; Ledgerwood GL
J Fam Pract; 2008 Feb; 57(2 Suppl Managing):S19-23. PubMed ID: 18662525
[TBL] [Abstract][Full Text] [Related]
16. [Infections and bacterial resistance in the community].
Goettsch WG; Goossens H; de Neeling AJ; Sprenger MJ
Ned Tijdschr Geneeskd; 1999 Jun; 143(25):1296-9. PubMed ID: 10416482
[TBL] [Abstract][Full Text] [Related]
17. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
18. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
Sbarbaro JA
Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
[No Abstract] [Full Text] [Related]
19. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
File TM
Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111
[TBL] [Abstract][Full Text] [Related]
20. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
Morrissey I; Colclough A; Northwood J
Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
